GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in Zhejiang, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its molecular glue degrading agent, GLB-002. The drug is indicated for the treatment of non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), among other conditions.
Mechanism of Action and Indications
GLB-002 is a CRBN E3 ligase regulator, classified as CELMoDs, with a novel chemical mother nucleus structure. It works by binding with CRL4CRBN E3 ligase CRBN, promoting the ubiquitination of transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). These factors are then degraded by proteasomes, activating various downstream anti-tumor reactions and exerting therapeutic effects on hematological tumors such as NHL and MM.
Preclinical Toxicological Study and Advantages
The preclinical toxicological study of GLB-002 has demonstrated its excellent pharmacokinetic properties and high selectivity, along with an enhanced treatment window. Compared to third-generation molecular glue drugs like iberdomide, golcadomide, and mezigdomide, which are still in clinical research and development, GLB-002 has shown significant improvements in its anti-tumor proliferation activity against NHL and MM resistant cell lines in vitro.
Conclusion
The clinical trial approval of GLB-002 by the NMPA is a significant step forward for GluBio Pharmaceutical in advancing a novel treatment option for patients with NHL and MM. With its promising preclinical results, GLB-002 has the potential to offer a more effective therapy for these hematological malignancies.-Fineline Info & Tech
